- $1.33bn
- $566.72m
- $117.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.87 | ||
| Price to Tang. Book | 2.87 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.33 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.32% | ||
| Return on Equity | -54.87% | ||
| Operating Margin | -290.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 15 | 77.52 | 382.88 | 112 | 117 | 191.65 | 166.61 | 69.54% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Directors
- Terry Rosen CHM (61)
- Juan Jaen PRE (63)
- Robert Goeltz CFO (48)
- Jennifer Jarrett COO (50)
- Carolyn Tang GCN (42)
- Yasunori Kaneko LED (67)
- Linda Higgins DRC
- Nicole Lambert DRC (47)
- Merdad Parsey DRC (58)
- Kathryn Falberg IND (60)
- David Lacey IND (68)
- Patrick Machado IND (56)
- Andrew Perlman IND (73)
- Antoni Ribas IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 30th, 2015
- Public Since
- March 15th, 2018
- No. of Shareholders
- 37
- No. of Employees
- 577
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 90,864,829
- Address
- 3928 Point Eden Way, HAYWARD, 94545-3719
- Web
- https://arcusbio.com/
- Phone
- +1 5106946200
- Auditors
- Ernst & Young LLP
Upcoming Events for RCUS
Arcus Biosciences Inc Annual Shareholders Meeting
Q2 2024 Arcus Biosciences Inc Earnings Release
Similar to RCUS
ADC Therapeutics SA
New York Stock Exchange
Alto Neuroscience
New York Stock Exchange
Annovis Bio
New York Stock Exchange
Biohaven
New York Stock Exchange
Charles River Laboratories International
New York Stock Exchange
FAQ
What is the Arcus Biosciences share price?
As of Today at 19:02 UTC, shares in Arcus Biosciences are trading at $14.59. This share price information is delayed by 15 minutes.
How has the Arcus Biosciences share price performed this year?
Shares in Arcus Biosciences last closed at $14.59 and the price had moved by -23.85% over the past 365 days. In terms of relative price strength the Arcus Biosciences share price has underperformed the S&P500 Index by -36.63% over the past year.
What are the analyst and broker recommendations for Arcus Biosciences?
The overall consensus recommendation for Arcus Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Arcus Biosciences dividend yield?
Arcus Biosciences does not currently pay a dividend.
Does Arcus Biosciences pay a dividend?
Arcus Biosciences does not currently pay a dividend.
When does Arcus Biosciences next pay dividends?
Arcus Biosciences does not currently pay a dividend.
How do I buy Arcus Biosciences shares?
To buy shares in Arcus Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Arcus Biosciences?
As of the previous close price of $14.59, shares in Arcus Biosciences had a market capitalisation of $1.33bn.
Where are Arcus Biosciences shares listed?
Here are the trading details for Arcus Biosciences:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: RCUS
What kind of share is Arcus Biosciences?
Based on an overall assessment of its quality, value and momentum Arcus Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Arcus Biosciences share price forecast for 2024?
The analyst consensus target price for shares in Arcus Biosciences is $39.20. That is 168.68% above the last closing price of $14.59.
Analysts covering Arcus Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$3.48 for the next financial year.
What is the trend in the Arcus Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arcus Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -23.16%.
As of the last closing price of $14.59, shares in Arcus Biosciences were trading -17.49% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Arcus Biosciences PE Ratio?
The Arcus Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $14.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Arcus Biosciences?
Arcus Biosciences' management team is headed by:
- Terry Rosen - CHM
- Juan Jaen - PRE
- Robert Goeltz - CFO
- Jennifer Jarrett - COO
- Carolyn Tang - GCN
- Yasunori Kaneko - LED
- Linda Higgins - DRC
- Nicole Lambert - DRC
- Merdad Parsey - DRC
- Kathryn Falberg - IND
- David Lacey - IND
- Patrick Machado - IND
- Andrew Perlman - IND
- Antoni Ribas - IND